23.100
+0.500
+(2.21%)
As of 9:57:46 AM GMT+8. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
12,098,090
10,103,806
9,382,410
9,935,141
8,690,234
Cost of Revenue
1,074,626
1,030,863
867,010
870,042
801,561
Gross Profit
11,023,464
9,072,943
8,515,400
9,065,099
7,888,673
Operating Expense
6,591,703
6,233,622
5,723,917
6,030,200
5,058,583
Operating Income
4,431,761
2,839,321
2,791,483
3,034,899
2,830,090
Net Non Operating Interest Income Expense
865,914
838,326
250,943
111,275
90,392
Pretax Income
5,384,458
3,766,155
2,948,428
3,300,082
3,098,299
Tax Provision
670,278
488,652
364,681
587,180
529,392
Net Income Common Stockholders
4,714,180
3,277,503
2,583,747
2,712,902
2,568,907
Average Dilution Earnings
-131,494
-131,759
--
-59,200
--
Diluted NI Available to Com Stockholders
4,582,686
3,145,744
2,583,747
2,653,702
2,568,907
Basic EPS
0.79
0.55
0.44
0.46
0.44
Diluted EPS
0.76
0.52
0.44
0.44
0.44
Basic Average Shares
5,925,920.504
5,924,899.050
5,915,822.196
5,921,040.161
5,876,243.659
Diluted Average Shares
6,021,192.162
6,019,650.142
5,929,483.310
5,997,857.724
5,878,078.730
Rent Expense Supplemental
--
5,457
8,651
--
--
Total Expenses
7,666,329
7,264,485
6,590,927
6,900,242
5,860,144
Net Income from Continuing & Discontinued Operation
4,714,180
3,277,503
2,583,747
2,712,902
2,568,907
Normalized Income
4,606,090.526
3,158,888.556
2,523,724.789
2,734,102.391
2,536,964.588
Interest Income
906,798
905,005
309,085
164,093
92,037
Interest Expense
40,884
66,679
58,142
52,818
1,645
Net Interest Income
865,914
838,326
250,943
111,275
90,392
EBIT
5,425,342
3,832,834
3,006,570
3,352,900
3,099,944
EBITDA
5,823,612
4,199,215
3,351,172
3,631,367
3,333,218
Reconciled Cost of Revenue
1,074,626
1,030,863
867,010
870,042
801,561
Reconciled Depreciation
398,270
366,381
344,602
278,467
233,274
Net Income from Continuing Operation Net Minority Interest
4,714,180
3,277,503
2,583,747
2,712,902
2,568,907
Total Unusual Items Excluding Goodwill
123,458
136,299
68,494
-25,789
38,525
Total Unusual Items
123,458
136,299
68,494
-25,789
38,525
Normalized EBITDA
5,700,154
4,062,916
3,282,678
3,657,156
3,294,693
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
15,368.526
17,684.556
8,471.789
-4,588.609
6,582.588
12/31/2020 - 6/14/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
3933.HK The United Laboratories International Holdings Limited
13.280
+6.24%
0512.HK GRAND PHARMA
5.780
+2.30%
3320.HK China Resources Pharmaceutical Group Limited
4.980
+1.43%
CASBF CanSino Biologics Inc.
3.2000
0.00%
1513.HK LIVZON PHARMA
26.650
+3.29%
0897.HK WAI YUEN TONG
0.350
+2.94%
6185.HK CanSino Biologics Inc.
31.000
+4.38%
2552.HK Hua Medicine (Shanghai) Ltd.
2.180
+6.86%
3613.HK Beijing Tong Ren Tang Chinese Medicine Company Limited
8.650
+1.76%
2877.HK China Shineway Pharmaceutical Group Limited
7.750
+2.11%